Optimizing Treatment forHER2-Positive Advanced Breast
Cancer
Program Goals
CLEOPATRA Study Design
First-Line Therapy of HER2+ MBC
Therapy of MBC After Progression on First-Line Anti-
HER2 Treatment
EMILIA: PFS
EMILIA: OS at Second Interim Analysis
EMILIA: Hematologic Adverse Events
First-Line Treatment With T-DM1 vs Trastuzumab +
Docetaxel
BOLERO-3: Previous Therapy